ELGX Key Stats
|Revenue (Quarterly YoY Growth)||24.59%|
|EPS Diluted (TTM)||-0.3059|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-19.17M|
|Gross Profit Margin (Quarterly)||77.87%|
|Profit Margin (Quarterly)||-27.03%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- ENDOLOGIX INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obl Dec 6
- 8:36 am Endologix priced a public offering of $75 million aggregate principal amount of convertible senior notes due 2018 Dec 5
- Endologix Announces Pricing of $75 Million of Convertible Notes GlobeNewswire Dec 5
- Endologix Announces Offering of $75 Million of Convertible Notes noodls Dec 3
- ENDOLOGIX INC /DE/ Files SEC form 8-K, Financial Statements and Exhibits Dec 3
- Endologix files to sell $75M of convertible senior notes due 2018 theflyonthewall.com Dec 3
- Endologix to Participate in Two Investor Conferences in December noodls Nov 25
- ENDOLOGIX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Nov 22
- Endologix, Inc. [ELGX] to Ring The NASDAQ Stock Market Opening Bell GlobeNewswire Nov 21
- Endologix's CEO Hosts Endologix Investor Meeting (Transcript) Seeking Alpha Nov 20
ELGX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Endologix is up 20.76% over the last year vs S&P 500 Total Return up 29.87%, Staar Surgical up 136.0%, and C.R. Bard up 42.17%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ELGX
Pro Report PDF for ELGX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ELGX Pro Report PDF
Pro Strategies Featuring ELGX
Did Endologix make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of Abdominal Aortic Aneurysms (AAA). The firm currently marketing Powerlink Delivery System an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. The company was founded in March 1992 and is headquartered in Irvine, California.